1. Home
  2. AIRT vs ENTX Comparison

AIRT vs ENTX Comparison

Compare AIRT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

HOLD

Current Price

$21.93

Market Cap

58.6M

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.34

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRT
ENTX
Founded
1980
2010
Country
United States
Israel
Employees
646
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
62.6M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
AIRT
ENTX
Price
$21.93
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.8K
184.9K
Earning Date
02-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.32
Revenue Growth
N/A
N/A
52 Week Low
$15.05
$0.91
52 Week High
$26.70
$3.22

Technical Indicators

Market Signals
Indicator
AIRT
ENTX
Relative Strength Index (RSI) 47.54 55.80
Support Level $20.85 $1.17
Resistance Level $23.82 $1.39
Average True Range (ATR) 0.58 0.12
MACD -0.01 0.03
Stochastic Oscillator 40.79 79.03

Price Performance

Historical Comparison
AIRT
ENTX

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: